ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Abstract Number: 1526

Utilizing Electronic Health Records to Identify Clinical Features of ANA-Positive Patients Imparting High Risk for Progression to Systemic Lupus Erythematosus
Abstract Number: 1527

Comparative Harms in Patients with Systemic Lupus Erythematosus Treated with Anifrolumab or Belimumab: A Multicenter Cohort Study Using the TriNetX Research Network
Abstract Number: 1528

Pulmonary Arterial Hypertension in Systemic Lupus Erythematosus: National Inpatient Sample Analysis
Abstract Number: 1529

Systemic Lupus Erythematous and Neuromyelitis Optica Overlap and Risk of Infection in Hospitalized Patients
Abstract Number: 1530

Belimumab-Treated Patients with Systemic Lupus Erythematosus Without Prior Immunosuppressant Use Have More Favorable Clinical Outcomes Than Those with Prior Use of an Immunosuppressant
Abstract Number: 1531

Prospective mRNA SARS-CoV-2 Additional Vaccination in Systemic Autoimmune Disease Patients on Immunosuppressive Medications in a Randomized Controlled Trial
Abstract Number: 1532

Not yet on Track: Retrospective Chart Analysis Reveals Physician’s Treatment Approaches in SLE Fall Short of New EULAR Guidance
Abstract Number: 1533

Imvotamab, a CD20-Targeted Bispecific IgM T Cell Engager, Effectively Depletes Low-Expressing CD20+ B Cells in Preclinical Models of Autoimmune Disease
Abstract Number: 1534

Use and Safety of Sodium-Glucose Cotransporter-2 Inhibitors Among Patients with Lupus Nephritis and Clinical Indications
Abstract Number: 1535

Variations in Tacrolimus Whole Blood Concentrations During Pregnancy and Its Implications for Therapeutic Drug Monitoring: A Systematic Review and Meta-analysis
Abstract Number: 1536

Prescription Rates of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Lupus Nephritis: A Comparative Study Across Specialties
Abstract Number: 1537

Discovery of VENT-03: A Novel Clinical cGAS Inhibitor for the Treatment of SLE and Other Autoimmune Diseases
Abstract Number: 1538

Patient Reported Outcomes Analyses from AURORA 1 Clinical Trial: Lupus Impact Tracker and LupusPRO
Abstract Number: 1539

Effectiveness & Safety of Early versus Late Use of Rituximab in Extra-renal Lupus: Real World Experience from a Tertiary Care Centre
Abstract Number: 1540

Project HOPE: HydrOxychloroquine Adherence ProjEct

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].